Skip to main content
ANIK
NASDAQ Industrial Applications And Services

Anika Therapeutics Details Q1 Financials, Revealing Increased Cash Burn and Restructuring Costs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$12.39
Mkt Cap
$166.035M
52W Low
$7.87
52W High
$16.24
52W Position info
57% above low
Off High info
24% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

ANIK sits 57% above its 52-week low of $7.87 on elevated volume (2.1× avg).

Summary

Anika Therapeutics' Q1 2026 report details a 13% revenue increase and improved gross margin, but also reveals a significant $16.4 million decrease in cash, driven by higher operating and financing outflows, alongside new restructuring charges and a tax valuation allowance.


Key Events · Earnings and Guidance · ANIK

  • Increased Cash Burn

    Cash and cash equivalents decreased by $16.4 million in Q1 2026, falling to $41.0 million from $57.5 million at year-end 2025. This was primarily due to $4.8 million used in operating activities and $10.3 million in financing activities, including share repurchases.

  • Restructuring Charges

    The company recognized $1.6 million in severance costs during Q1 2026 as part of a workforce reduction plan, with total expected restructuring costs of approximately $2.3 million.

  • Executive Compensation Expense

    A $3.3 million stock-based compensation expense was recognized in Q1 2026 related to the transition of the former Chief Executive Officer to Executive Chair.

  • Tax Valuation Allowance

    A full valuation allowance was recorded against domestic deferred tax assets, reflecting prior year operating losses and uncertainty regarding the realizability of these assets in the U.S.


Analysis · ANIK · Industrial Applications And Services

This 10-Q provides a comprehensive look into Anika Therapeutics' first-quarter financial performance, expanding on the preliminary results likely disclosed in a recent 8-K. While revenue growth and gross margin improvement are positive, the report highlights a significant increase in cash used for operations and financing, leading to a substantial reduction in the cash balance. The recognition of restructuring costs and a full valuation allowance against domestic deferred tax assets signal ongoing challenges and a cautious outlook on future U.S. profitability. Investors should monitor the company's cash management and the impact of restructuring efforts on future expenses and operational efficiency.

At the time of this filing, ANIK was trading at $12.39 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $166M. The 52-week trading range was $7.87 to $16.24. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANIK - Latest Insights

ANIK
Jul 29, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.50
Real-time Price: $15.86 info
Change: +$0.360 (+2%) info
Market Cap: $211.027M info
ANIK
Jun 23, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.59
Real-time Price: $15.86 info
Change: +$1.27 (+9%) info
Market Cap: $211.027M info
ANIK
Jun 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.59
Real-time Price: $15.86 info
Change: +$1.27 (+9%) info
Market Cap: $211.027M info
ANIK
Jun 08, 2026, 9:25 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $14.48
Real-time Price: $15.86 info
Change: +$1.38 (+10%) info
Market Cap: $211.027M info
ANIK
Jun 01, 2026, 11:12 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $13.98
Real-time Price: $15.86 info
Change: +$1.88 (+13%) info
Market Cap: $211.027M info